REVIEW
Flavonoids as anticancer therapies: A systematic review of clinical trials
Ângela Bisol,
Paloma Santos de Campos,
Marcelo Lazzaron Lamers,
Ângela Bisol
Basic Research Center in Dentistry, Dentistry School, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Search for more papers by this authorPaloma Santos de Campos
Basic Research Center in Dentistry, Dentistry School, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Search for more papers by this authorCorresponding Author
Marcelo Lazzaron Lamers
Basic Research Center in Dentistry, Dentistry School, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Department of Morphological Sciences, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Correspondence
Marcelo Lazzaron Lamers, Department of Morphological Sciences, Institute of Basic Health Science, Federal University of Rio Grande do Sul, Rua Sarmento Leite, 500, subsolo, Porto Alegre, Rio Grande do Sul, Brazil.
Email: [email protected]
Search for more papers by this authorÂngela Bisol,
Paloma Santos de Campos,
Marcelo Lazzaron Lamers,
Ângela Bisol
Basic Research Center in Dentistry, Dentistry School, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Search for more papers by this authorPaloma Santos de Campos
Basic Research Center in Dentistry, Dentistry School, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Search for more papers by this authorCorresponding Author
Marcelo Lazzaron Lamers
Basic Research Center in Dentistry, Dentistry School, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Department of Morphological Sciences, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Correspondence
Marcelo Lazzaron Lamers, Department of Morphological Sciences, Institute of Basic Health Science, Federal University of Rio Grande do Sul, Rua Sarmento Leite, 500, subsolo, Porto Alegre, Rio Grande do Sul, Brazil.
Email: [email protected]
Search for more papers by this authorAbstract
Flavonoids have been proposed as potential chemotherapeutic agents because they are toxic against cancer cells but not harmful to healthy cells. This systematic review analyzed flavonoid effectiveness in human cancer chemotherapy. Overall, 22 phase II and 1 phase III clinical trials (PubMed, Scopus, and Web of Science) that used flavonoids as a single agent or combined with other therapeutics against hematopoietic/lymphoid or solid cancer published by January 2019 were selected for analysis. Flavopiridol was the most commonly used flavonoid (at a dose of 50-mg/m2 IV) for all tumor types. Aside from the relatively low rate of complete response (CR) or partial response (PR) with any administration protocol, flavonoids showed higher positive outcomes for hematopoietic and lymphoid tissues (140 patients with CR and 88 with PR among 615 patients in 11 trials) than for solid tumors (4 patients with CR and 21 with PR among 525 patients in 12 trials). However, because of the high variety in administration schedule, more studies are needed to further understand how flavonoids can promote positive outcomes for cancer patients.
CONFLICT OF INTEREST
The authors declare no conflicts of interests.
REFERENCES
- Agullo, G., Gamet-Payrastre, L., Fernandez, Y., Anciaux, N., Demigne, C., & Remesy, C. (1996). "Comparative effects of flavonoids on the growth, viability and metabolism of a colonic adenocarcinoma cell line (HT29 cells)." (2005). Cancer Lett, 105(1), 61–70. https://doi.org/10.1016/0304-3835(96)04262-0
- Abbaszadeh, H., Keikhaei, B., & Mottaghi, S. (2019). A review of molecular mechanism sinvolved in anticancer and antiangiogenic effects of natural polyphenolic compounds. Phytotherapy Research., 33, 2002–2014. https://doi.org/10.1002/ptr.6403
- Aklilu, M., Kindler, H. L., Donehower, R. C., Mani, S., & Vokes, E. E. (2003). Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol, 14(8), 1270–1273. https://doi.org/10.1093/annonc/mdg343
- Amorati, R., & Valgimigli, L. (2012). Modulation of the antioxidant activity of phenols by non-covalent interactions. Org Biomol Chem, 10(21), 4147–4158.
- Barthelman, M., Bair, W. B. 3rd, Stickland, K. K., Chen, W., Timmermann, B. N., Valcic, S., … Bowden, G. T. (1998). (-)-Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity. Carcinogenesis, 19(12), 2201–2204. https://doi.org/10.1093/carcin/19.12.2201
- Berman, A. Y., Motechin, R. A., Wiesenfeld, M. Y., & Holz, M. K. (2017). The therapeutic potential of resveratrol: A review of clinical trials. NPJ Precis Oncol, 1.
- Bhise, K., Kashaw, S. K., Sau, S., & Iyer, A. K. (2017). Nanostructured lipid carriers employing polyphenols as promising anticancer agents: Quality by design (QbD) approach. Int J Pharm, 526(1-2), 506–515.
- Bible, K. C., Peethambaram, P. P., Oberg, A. L., Maples, W., Groteluschen, D. L., Boente, M., … Erlichman, C. (2012). A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol, 127(1), 55–62. https://doi.org/10.1016/j.ygyno.2012.05.030
- Bravo, L. (1998). Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev, 56(11), 317–333.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer: J Clin.
- Brusselmans, K., De Schrijver, E., Heyns, W., Verhoeven, G., & Swinnen, J. V. (2003). Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer, 106(6), 856–862. https://doi.org/10.1002/ijc.11317
- Brusselmans, K., Vrolix, R., Verhoeven, G., & Swinnen, J. V. (2005). Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem, 280(7), 5636–5645. https://doi.org/10.1074/jbc.M408177200
- Burdette-Radoux, S., Tozer, R. G., Lohmann, R. C., Quirt, I., Ernst, D. S., Walsh, W., … Eisenhauer, E. A. (2004). Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs, 22(3), 315–322. https://doi.org/10.1023/B:DRUG.0000026258.02846.1c
- Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., … Grever, M. R. (2007). Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 109(2), 399–404.
- Byrd, J. C., Peterson, B. L., Gabrilove, J., Odenike, O. M., Grever, M. R., Rai, K., & Larson, R. A. (2005). Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from Cancer and Leukemia Group B study 19805. Clin Cancer Res, 11(11), 4176–4181.
- Carvajal, R. D., Tse, A., Shah, M. A., Lefkowitz, R. A., Gonen, M., Gilman-Rosen, L., … O'Reilly, E. M. (2009). A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology, 9(4), 404–409. https://doi.org/10.1159/000187135
- Chabner, B. A., & Roberts, T. G. Jr. (2005). Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer. England., 5, 65–72.
- Crozier, A., Jaganath, I. B., & Clifford, M. N. (2009). Dietary phenolics: Chemistry, bioavailability and effects on health. Nat Prod Rep, 26(8), 1001–1043. https://doi.org/10.1039/b802662a
- Damianaki, A., Bakogeorgou, E., Kampa, M., Notas, G., Hatzoglou, A., Panagiotou, S., … Castanas, E. (2000). Potent inhibitory action of red wine polyphenols on human breast cancer cells. J Cell Biochem, 78(3), 429–441. https://doi.org/10.1002/1097-4644(20000901)78:3<429::aid-jcb8>3.0.co;2-m
- Davatgaran-Taghipour, Y., Masoomzadeh, S., Farzaei, M. H., Bahramsoltani, R., Karimi-Soureh, Z., Rahimi, R., & Abdollahi, M. (2017). Polyphenol nanoformulations for cancer therapy: Experimental evidence and clinical perspective. Int J Nanomedicine, 12, 2689–2702.
- Dong, Z., Ma, W., Huang, C., & Yang, C. S. (1997). Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res, 57(19), 4414–4419.
- Dong, J. Y., & Quin, L. Q. (2011). Soy isoflavone consumption and risk of breast cancer incidence or recurrence: A meta-analysis of propspctive studies. Breast cancer Research and Treatment, 125(2), 315–323.
- Durazzo, A., Lucarini, M., Souto, E. B., et al. (2019). Polyphenols: A concise overview on the chemistry, occurrence, and human health. Phytotherapy Research., 1–23.
- El-Rayes, B. F., Philip, P. A., Sarkar, F. H., Shields, A. F., Ferris, A. M., Hess, K., … Abbruzzese, J. L. (2011). A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs, 29(4), 694–699.
- Flinn, I. W., Byrd, J. C., Bartlett, N., Kipps, T., Gribben, J., Thomas, D., … Grever, M. R. (2005). Flavopiridol administered as a 24-hours continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res, 29(11), 1253–1257. https://doi.org/10.1016/j.leukres.2005.03.010
- Fotopoulou, C., Vergote, I., Mainwaring, P., Bidzinski, M., Vermorken, J. B., Ghamande, S. A., … Gabra, H. (2014). Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: The phase III OVATURE multicenter randomized study. Ann Oncol, 25(1), 160–165. https://doi.org/10.1093/annonc/mdt515
- Fu, B., Xue, J., Li, Z., Shi, X., Jiang, B. H., & Fang, J. (2007). Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Mol Cancer Ther, 6(1), 220–226. https://doi.org/10.1158/1535-7163.MCT-06-0526
- Galati, G., Sabzevari, O., Wilson, J. X., & O'Brien, P. J. (2002). Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology, 177(1), 91–104.
- Gamble JR, Xia P, Hahn CN et al. (2006) "Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects.” Int J Cancer 118(10), 2412–2420.
- Gan, H. K., You, B., Pond, G. R., & Chen, E. X. (2012). Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst, 104(8), 590–598. https://doi.org/10.1093/jnci/djs141
- Gerlinger, M., Rowan, A. J., Horswell, S., Math, M., Larkin, J., Endesfelder, D., … Swanton, C. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med, 366(10), 883–892. https://doi.org/10.1056/NEJMoa1113205
- Grendys, E. C. Jr., Blessing, J. A., Burger, R., & Hoffman, J. (2005). A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: A gynecologic oncology group study. Gynecol Oncol, 98(2), 249–253. https://doi.org/10.1016/j.ygyno.2005.05.017
- Grosso, G G.. Lamueda R. R, Ray S., Micey A. et al (2007) “A comprehensive meta-analysis on dietary flavonoid and lignant ad cancer risk: Level of evidence and limitations.” Molecular Nutrition and Food Research. 61(4).
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013
- He, Q., Kim, J., & Sharma, R. P. (2004). Silymarin protects against liver damage in BALB/c mice exposed to fumonisin B1 despite increasing accumulation of free sphingoid bases. Toxicol Sci, 80(2), 335–342. https://doi.org/10.1093/toxsci/kfh148
- Heim, K. E., Tagliaferro, A. R., & Bobilya, D. J. (2002). Flavonoid antioxidants: Chemistry, metabolism and structure-activity relationships. J Nutr Biochem, 13(10), 572–584.
- Henning, S. M., Wang, P., Said, J. W., Huang, M., Grogan, T., Elashoff, D., … Aronson, W. J. (2015). Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate, 75(5), 550–559. https://doi.org/10.1002/pros.22943
- Hourigan, C. S., & Karp, J. E. (2011). New considerations in the design of clinical trials for the treatment of acute leukemia. Clin Investig (Lond), 1(4), 509–517. https://doi.org/10.4155/cli.11.24
- Huang, C., Chen, X., Guo, B., Huang, W., Shen, T., Sun, X., … Zhou, Q. (2012). Induction of apoptosis by Icariside II through extrinsic and intrinsic signaling pathways in human breast cancer MCF7 cells. Biosci Biotechnol Biochem, 76(7), 1322–1328.
- Jadad, A. R., Carroll, D., Moore, A., & McQuay, H. (1996). Developing a database of published reports of randomised clinical trials in pain research. Pain, 66(2-3), 239–246. https://doi.org/10.1016/0304-3959(96)03033-3
- Kamsteeg, M., Rutherford, T., Sapi, E., Hanczaruk, B., Shahabi, S., Flick, M., … Mor, G. (2003). Phenoxodiol—an isoflavone analog—induces apoptosis in chemoresistant ovarian cancer cells. Oncogene, 22(17), 2611–2620. https://doi.org/10.1038/sj.onc.1206422
- Karp, J. E., Blackford, A., Smith, B. D., Alino, K., Seung, A. H., Bolanos-Meade, J., … Wright, J. J. (2010). Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res, 34(7), 877–882. https://doi.org/10.1016/j.leukres.2009.11.007
- Karp, J. E., Garrett-Mayer, E., Estey, E. H., Rudek, M. A., Smith, B. D., Greer, J. M., … Pagel, J. M. (2012). Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica, 97(11), 1736–1742. https://doi.org/10.3324/haematol.2012.062539
- Karp, J. E., Smith, B. D., Levis, M. J., Gore, S. D., Greer, J., Hattenburg, C., … Colevas, A. D. (2007). Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res, 13(15 Pt 1), 4467–4473. https://doi.org/10.1158/1078-0432.CCR-07-0381
- Kamsteeg M, Rutherford T, Sapi E, et al. (2003) “Phenoxodiol V an isoflavone analogue V induces apoptosis in chemo-resistant ovarian cancer cells.” Oncogene. (22), 2611-2620.
- Katayama, K., Masuyama, K., Yoshioka, S., Hasegawa, H., Mitsuhashi, J., & Sugimoto, Y. (2007). Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: Transporter specificity and structure-activity relationship. Cancer Chemother Pharmacol, 60(6), 789–797. https://doi.org/10.1007/s00280-007-0426-7
- Kaye, S. B., Clavel M., Dodion P., Monfardini S., Bokkel-Huinink ten W., Wagener D. T., Gundersen S., Stoter G., Smith J., Renard J. and et al. (1990). “Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma.” Invest New Drugs 8 Suppl 1, S95-99.
- Kelly, M. G., Mor, G., Husband, A., O'Malley, D. M., Baker, L., Azodi, M., … Rutherford, T. J. (2011). Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Int J Gynecol Cancer, 21(4), 633–639. https://doi.org/10.1097/IGC.0b013e3182126f05
- Khan, M. S., Halagowder, D., & Devaraj, S. N. (2011). Methylated chrysin induces co-ordinated attenuation of the canonical Wnt and NF-kB signaling pathway and upregulates apoptotic gene expression in the early hepatocarcinogenesis rat model. Chem Biol Interact, 193(1), 12–21. https://doi.org/10.1016/j.cbi.2011.04.007
- Karthikeyan, S., Srinivasan, R., Wani, S. A., & Manoharan, S. (2013). Chemopreventive potential of chrysin in 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis. Int J Nutr Pharmacol Neurol Dis., 3(4), 46–53.
- Kouroukis, C. T., Belch, A., Crump, M., Eisenhauer, E., Gascoyne, R. D., & Meyer, R. R. Lohmann. P..
- Li, A. N., Li, S., Zhang, Y. J., Xu, X. R., Chen, Y. M., & Li, H. B. (2014). Resources and biological activities of natural polyphenols. Nutrients, 6(12), 6020–6047. https://doi.org/10.3390/nu6126020
- Lopez, J., Powers, R. T., & Connors, J. M. (2003). Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 21(9), 1740–1745.
- Koval, A., Pieme, C. A., Queiroz, E. F., Ragusa, S., Ahmed, K., Blagodatski, A., … Katanaev, V. L. (2018). Tannins from Syzygium guineense suppress Wnt signaling and proliferation of Wnt-dependent tumors through a direct effect on secreted Wnts. Cancer Lett, 435, 110–120.
- Kumar, S., & Pandey, A. K. (2013). Chemistry and biological activities of flavonoids: An overview. ScientificWorldJournal, 2013, 162750.
- Kuntz, S., Wenzel, U., & Daniel, H. (1999). Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J Nutr, 38(3), 133–142. https://doi.org/10.1007/s003940050054
- Yan, L., & Spitznagel, E. L. (2009). Soy consumption and prostate cancer risk in men. A revisit of a meta-analysis. The American Journal of Clinical Nutrition, 89(4), 1155–1163.
- Lamson, D. W., & Brignall, M. S. (2000). Antioxidants and cancer, part 3: Quercetin. Altern Med Rev, 5(3), 196–208.
- Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. (2004) “VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3- gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood”.104(3):788–94.
- Lin, C. C., Yu, C. S., Yang, J. S., Lu, C. C., Chiang, J. H., Lin, J. P., … Chung, J. G. (2012). Chrysin, a natural and biologically active flavonoid, influences a murine leukemia model in vivo through enhancing populations of T-and B-cells, and promoting macrophage phagocytosis and NK cell cytotoxicity. Vivo, 26(4), 665–670.
- Lin, S. C., Li, W. C., Shih, J. W., Hong, K. F., Pan, Y. R., & Lin, J. J. (2006). The tea polyphenols EGCG and EGC repress mRNA expression of human telomerase reverse transcriptase (hTERT) in carcinoma cells. Cancer Lett, 236(1), 80–88. https://doi.org/10.1016/j.canlet.2005.05.003
- Lin, T. S., Howard, O. M., Neuberg, D. S., Kim, H. H., & Shipp, M. A. (2002). Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma, 43(4), 793–797. https://doi.org/10.1080/10428190290016908
- Lin, T. S., Ruppert, A. S., Johnson, A. J., Fischer, B., Heerema, N. A., Andritsos, L. A., … Byrd, J. C. (2009). Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol, 27(35), 6012–6018. https://doi.org/10.1200/JCO.2009.22.6944
- Liu, H., Hwang, J., Li, W., Choi, T. W., Liu, K., Huang, Z., … Dong, Z. (2014). A derivative of chrysin suppresses two-stage skin carcinogenesis by inhibiting mitogen- and stress-activated kinase 1. Cancer Prev Res (Phila), 7(1), 74–85.
- Lv, Y., Yang, Z., Zhao, L., Zhao, S., Han, J., & Zheng, L. (2015). The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials. Int J Clin Exp Med, 8(1), 334–345.
- Martinez-Perez, C., Ward, C., Cook, G., Mullen, P., McPhail, D., Harrison, D. J., & Langdon, S. P. (2014). Novel flavonoids as anti-cancer agents: Mechanisms of action and promise for their potential application in breast cancer. Biochem Soc Trans, 42(4), 1017–1023. https://doi.org/10.1042/BST20140073
- McLarty, J., Bigelow, R. L., Smith, M., Elmajian, D., Ankem, M., & Cardelli, J. A. (2009). Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila), 2(7), 673–682.
- Mishra, A., Sharma, A. K., Kumar, S., Saxena, A. K., & Pandey, A. K. (2013). Bauhinia variegata leaf extracts exhibit considerable antibacterial, antioxidant, and anticancer activities. Biomed Res Int, 2013, 915436.
- Nakazato T, Ito K, Ikeda Y, Kizaki M. (2005) “Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species.” Clin Cancer Res.; 11(16):6040– 9Pandey et al., (2009) KB, Rizvi S. (2009) “Plant polyphenols as dietary antioxidants in human health and disease.” Oxidative Medicine and Cellular Longevity 2(5) 270-278.
- Pavese J.M., Krishna S. N. and Bergman R.C.(2014). “Gennistein inhibits human prostate cancer cell detachment, invasion and metastasis.” The American Journal Of Clinical Nutrition, 100(suppl_1),4315-4365
- Park, K. I., Park, H. S., Nagappan, A., Hong, G. E., Lee, D. H., Kang, S. R., … Kim, G. S. (2012). Induction of the cell cycle arrest and apoptosis by flavonoids isolated from Korean Citrus aurantium L. in non-small-cell lung cancer cells. Food Chem, 135(4), 2728–2735. https://doi.org/10.1016/j.foodchem.2012.06.097
- Park, S. (2015). Polyphenol compound as a transcription factor inhibitor. Nutrients, 7(11), 8987–9004.
- Perez-Herrero, E., & Fernandez-Medarde, A. (2015). Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm, 93, 52–79. https://doi.org/10.1016/j.ejpb.2015.03.018
- Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nat Med, 19(11), 1423–1437. https://doi.org/10.1038/nm.3394
- Ramirez-Garza, S. L., Laveriano-Santos, E. P., Marhuenda-Munoz, M., Storniolo, C. E., Tresserra-Rimbau, A., Vallverdu-Queralt, A., & Lamuela-Raventos, R. M. (2018). Health Effects of Resveratrol: Results from Human Intervention Trials. Nutrients, 10(12).
- Ramos, S. (2007). Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J Nutr Biochem, 18(7), 427–442. https://doi.org/10.1016/j.jnutbio.2006.11.004
- Rothwell, J. A., Knaze, V., & Zamora, R. (2017). Polyphenols: Dietary assessment and role in the prevention of cancers. Current Opinion in Clinical Nutrition and Metabolic Care, 20(6), 512–521. https://doi.org/10.1097/MCO.0000000000000424
- Sapi, E., Chen, W., O'Malley, D., et al. (2004). Resistance of ovarian cancer cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Anticancer Drugs.. 14, 567-578.
- Seltzer, J. H., Gintant, G., Amiri-Kordestani, L., Singer, J., Koplowitz, L. P., Moslehi, J. J., … Yu, A. F. (2019). Assessing cardiac safety in oncology drug development. Am Heart J, 214, 125–133. https://doi.org/10.1016/j.ahj.2019.04.010
- Shanafelt, T. D., Lee, Y. K., Call, T. G., Nowakowski, G. S., Dingli, D., Zent, C. S., & Kay, N. E. (2006). Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res., 30, 707–712. https://doi.org/10.1016/j.leukres.2005.10.020
- Shanafelt, T. D., Call, T. G., Zent, C. S., Leis, J. F., LaPlant, B., Bowen, D. A., … Kay, N. E. (2013). Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer, 119(2), 363–370. https://doi.org/10.1002/cncr.27719
- Sheng, H., Ogawa, T., Niwano, Y., Sasaki, K., & Tachibana, K. (2018). Effects of polyphenols on doxorubicin-induced oral keratinocyte cytotoxicity and anticancer potency against oral cancer cells. J Oral Pathol Med, 47(4), 368–374.
- Tan, K. W., Li, Y., Paxton, J. W., Birch, N. P., & Scheepens, A. (2013). Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). Food Chem, 138(4), 2267–2274.
- Tenta, R., Fragopoulou, E., Tsoukala, M., Xanthopoulou, M., Skyrianou, M., Pratsinis, H., & Kletsas, D. (2017). Antiproliferative effects of red and white wine extracts in PC-3 prostate cancer cells. Nutr Cancer, 69(6), 952–961. https://doi.org/10.1080/01635581.2017.1340489
- Thatcher, N., Dazzi, H., Mellor, M., Ghosh, A., Carrington, B., Johnson, R. J., … Craig, R. P. (1990). Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: A phase II study. Br J Cancer, 61(4), 618–621. https://doi.org/10.1038/bjc.1990.137
- Vaishampayan, U., Hussain, M., Banerjee, M., Seren, S., Sarkar, F. H., Fontana, J., … Kucuk, O. (2007). Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer, 59(1), 1–7.
- Van Veldhuizen, P. J., Faulkner, J. R., Lara, P. N. Jr., Gumerlock, P. H., Goodwin, J. W., Dakhil, S. R., … Crawford, E. D. (2005). A phase II study of flavopiridol in patients with advanced renal cell carcinoma: Results of Southwest Oncology Group Trial 0109. Cancer Chemother Pharmacol, 56(1), 39–45. https://doi.org/10.1007/s00280-004-0969-9
- Walter, R. B., Appelbaum, F. R., Tallman, M. S., Weiss, N. S., Larson, R. A., & Estey, E. H. (2010). Shortcomings in the clinical evaluation of new drugs: Acute myeloid leukemia as paradigm. Blood, 116(14), 2420–2428. https://doi.org/10.1182/blood-2010-05-285387
- Wang, C. G., Yao, W. N., Zhang, B., Hua, J., Liang, D., & Wang, H. S. (2018). Lung cancer and matrix metalloproteinases inhibitors of polyphenols from Selaginella tamariscina with suppression activity of migration. Bioorg Med Chem Lett, 28(14), 2413–2417. https://doi.org/10.1016/j.bmcl.2018.06.024
- Wu, J. C., Lai, C. S., Lee, P. S., et al. (2016). Anticancer efficacy of dietary polyphenols is mediated through epigenetic modifications. Current opinion in Food science, 9, 1–7.
- Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., … Karp, J. E. (2015). Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica, 100(9), 1172–1179. https://doi.org/10.3324/haematol.2015.125849
- Zhang, S., Yang, X., Coburn, R. A., & Morris, M. E. (2005). Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol, 70(4), 627–639.
- Zhu, W., Jia, Q., Wang, Y., Zhang, Y., & Xia, M. (2012). The anthocyanin cyanidin-3-O-beta-glucoside, a flavonoid, increases hepatic glutathione synthesis and protects hepatocytes against reactive oxygen species during hyperglycemia: Involvement of a cAMP-PKA-dependent signaling pathway. Free Radic Biol Med, 52(2), 314–327.
Citing Literature
